Background. During the period of 1996–1999, we prospectively monitored 243 Javanese
adults and children after arriving in Papua, Indonesia, and microscopically documented …

Abstract Background The World Health Organization (WHO) recommends Artemisinin‐
based Combination Therapy (ACT) for treating uncomplicated Plasmodium falciparum …

Malaria mortality in human populations varies greatly under different circumstances. The
intense malaria transmission conditions found in many parts of tropical Africa, the much …

The deployment of artesunate for severe malaria and the artemisinin combination therapies
(ACTs) for uncomplicated malaria has been a major advance in antimalarial therapeutics …

The increasing frequency of therapeutic failures in falciparum malaria underscores the need
for novel, rapidly effective antimalarial drugs or drug combinations. Atovaquone and …

Malaria causes substantial morbidity and mortality in many of the most resource-limited
areas of the world. In addition, malaria is a threat to travelers to endemic areas and should …

Background Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia.
Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country. The …

BACKGROUND: With the emergence of multidrug-resistant falciparum malaria, new drugs
and drugs in combination are urgently needed. METHODS: New antimalarial drugs …

Background Chloroquine has been recommended for Plasmodium vivax infections for> 60
years, but resistance is increasing. To guide future therapies, the cumulative benefits of …

Malaria is the tropical disease most commonly imported into the UK, with 1500–2000 cases
reported each year, and 10–20 deaths. Approximately three-quarters of reported malaria …